3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma

Peritoneal Dialysis International

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Erixon, Martin ^a   Wieslander, Anders ^a   Lindén, Torbjörn ^a   Carlsson, Ola ^a   Jönsson, Jan Åke ^a   Simonsen, Ole ^b   Kjellstrand, Per ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

3,4 DGE; 3 DG; Advanced glycation end products; Glucose degradation products; Peritoneal dialysis fluid; Plasma

Indexed keywords

3 DEOXYGLUCOSONE; 3,4 DIDEOXYGLUCOSONE 3 ENE; DIANEAL; GAMBROSOL TRIO; GLUCOSE DEGRADATION PRODUCT; PERITONEAL DIALYSIS FLUID; UNCLASSIFIED DRUG; 3,4-DIDEOXYGLUCOSONE-3-ENE; ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLYCOGEN PHOSPHORYLASE; PYRONE DERIVATIVE;

ANIMAL EXPERIMENT; BLOOD ANALYSIS; BLOOD LEVEL; CHEMICAL ANALYSIS; CONFERENCE PAPER; HUMAN; MALE; NONHUMAN; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RAT; ANIMAL; ARTICLE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PERITONEUM; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIALYSIS SOLUTIONS; DISEASE MODELS, ANIMAL; GLYCOGEN PHOSPHORYLASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INJECTIONS, INTRAPERITONEAL; KIDNEY FAILURE, CHRONIC; MALE; PERITONEAL DIALYSIS; PERITONEUM; PYRONES; RATS; RATS, WISTAR;

EID: 67449100957     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902902s04     Document Type: Conference Paper

References (6)

1. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
2. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893-9.
3. Erixon M, Lindén T, Kjellstrand P, Carlsson O, Ernebrant M, Forsback G, et al. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Perit Dial Int 2004; 24:392-8.
4. Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R. Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 2000; 20(Suppl 5):S23-7.
5. Carlsson O, Rosengren BI, Rippe B. Effects of peritoneal hyaluronidase treatment on transperitoneal solute and fluid transport in the rat. Acta Physiol Scand 2000; 168: 371-6.
6. Lamb EJ, Cattell WR, Dawnay ABJ. In vitro formation of advanced glycation end products in peritoneal dialysis fluid. Kidney Int 1995; 47:1768-74.